We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

47 hedge funds and large institutions have $21.1M invested in Insight Molecular Diagnostics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

7% more capital invested

Capital invested by funds: $19.7M → $21.1M (+$1.4M)

0.44% more ownership

Funds ownership: 2.35% → 2.79% (+0.44%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less funds holding

Funds holding: 52 → 47 (-5)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
47
Holders Change
-5
Holders Change %
-9.62%
% of All Funds
0.74%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
13
Reduced
7
Closed
11
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadwood Capital
New York
+$6.76M
2
AIC
AWM Investment Company
New York
+$1.87M
3
Morgan Stanley
Morgan Stanley
New York
+$694K
4
Citadel Advisors
Citadel Advisors
Florida
+$63.5K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$59.5K

Top Sellers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
-$136K
2
PM
Penbrook Management
New York
-$73.6K
3
BCM
Bridgeway Capital Management
Texas
-$72.8K
4
BlackRock
BlackRock
New York
-$53.7K
5
Millennium Management
Millennium Management
New York
-$34.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
26
Osaic Holdings
Arizona
$5.62K – – –
SSA
27
Schonfeld Strategic Advisors
New York
$4.53K -$453 -90 -8%
Victory Capital Management
28
Victory Capital Management
Texas
$3.78K +$1.15K +229 +39%
WJWM
29
Williams Jones Wealth Management
New York
$3.45K – – –
RJFSA
30
Raymond James Financial Services Advisors
Florida
$3.4K – – –
Creative Planning
31
Creative Planning
Kansas
$2.79K +$3.06K +607 New
LCS
32
Levin Capital Strategies
New York
$2.42K – – –
PNC Financial Services Group
33
PNC Financial Services Group
Pennsylvania
$2.3K – – –
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$1K +$695 +138 +476%
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$958 – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$714 – – –
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$304 +$332 +66 New
Wells Fargo
38
Wells Fargo
California
$259 +$81 +16 +40%
RAM
39
Riggs Asset Management
Pennsylvania
$230 – – –
PSB
40
Piscataqua Savings Bank
New Hampshire
$115 – – –
US Bancorp
41
US Bancorp
Minnesota
$115 – – –
MAM
42
Meeder Asset Management
Ohio
$45 – – –
CAS
43
Coppell Advisory Solutions
Texas
$44 +$50 +10 New
AFG
44
Albion Financial Group
Utah
$35 – – –
LC
45
Lindbrook Capital
California
$20 – – –
AWM
46
Avior Wealth Management
Nebraska
$3 – – –
Fidelity Investments
47
Fidelity Investments
Massachusetts
$2 – – –
PM
48
Penbrook Management
New York
– -$73.6K -10,384 Closed
BCM
49
Bridgeway Capital Management
Texas
– -$72.8K -10,265 Closed
Charles Schwab
50
Charles Schwab
California
– -$22.1K -3,114 Closed
1
2
3

IMDX Hedge Fund Activity: Q2 2023 in Review

47 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2023, worth a combined $21.1M — up 7.1% from $19.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of IMDX and 6 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 13 added.

The largest buyer was Broadwood Capital, adding an estimated $6.76M. The largest seller was Pura Vida Investments, cutting an estimated $136K.

  • 47 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2023, down from 52 in Q1 2023.
  • Funds reported $21.1M of Insight Molecular Diagnostics stock for Q2 2023, up 7.1% quarter-over-quarter.
  • 6 funds opened new Insight Molecular Diagnostics positions in Q2 2023 and 11 closed out, a net change of -5 holders.
  • The largest Insight Molecular Diagnostics buyer in Q2 2023 was Broadwood Capital, an estimated $6.76M added.
  • The largest Insight Molecular Diagnostics seller in Q2 2023 was Pura Vida Investments, an estimated $136K sold.

Based on aggregated 13F filings for Q2 2023.